Hydroxyurea is not officially classified as an immunosuppressant. It belongs to a drug class called antimetabolites, and it was originally developed as an anticancer medication. However, it does suppress bone marrow activity, which lowers white blood cell counts significantly. This myelosuppressive effect means hydroxyurea weakens parts of the immune system in practice, even though immunosuppression isn’t its primary purpose.
How Hydroxyurea Actually Works
Hydroxyurea targets an enzyme that cells need to build DNA. By blocking this enzyme, the drug starves rapidly dividing cells of the raw materials they require to copy their genetic code. Cells that are actively multiplying get stuck partway through division and can’t proceed normally.
This matters because the cells most affected are the ones dividing fastest: cancer cells, yes, but also bone marrow cells that produce blood components, including immune cells. That’s why hydroxyurea is described as a myelosuppressive agent. It slows down the bone marrow’s production line, reducing the number of white blood cells, platelets, and young red blood cells released into the bloodstream.
The Effect on White Blood Cells
The drop in immune cells is substantial and well-documented. In a cohort study of children with sickle cell disease, total white blood cell counts fell from about 20,800 to 14,600 per microliter after at least one year of treatment. Neutrophils, the white blood cells that serve as your front-line defense against bacterial infections, dropped by roughly 42%, from 9,770 to 5,680 per microliter. Lymphocytes, monocytes, and basophils also decreased, though less dramatically.
For sickle cell disease, this reduction is actually part of the point. Elevated white blood cell counts are linked to worse outcomes in sickle cell patients, contributing to inflammation and blood vessel blockage. Lowering the count is considered a therapeutic benefit, not just a side effect. Doctors intentionally increase the dose until they see mild suppression of blood counts, a target called “maximum tolerated dose.”
Does It Increase Infection Risk?
This is where the story takes a somewhat surprising turn. Despite lowering white blood cell counts, hydroxyurea does not appear to raise infection rates in sickle cell patients. A large study tracking over 4,700 patient-years of observation in African children with sickle cell anemia found that infection rates actually decreased during hydroxyurea treatment. Upper respiratory infections dropped by about 41%, lower respiratory infections by 73%, and skin infections by 62%. Non-malarial infections overall were cut by more than half.
Children in that study who contracted serious infections, including tuberculosis, HIV, varicella (chickenpox), measles, and parvovirus, had clinical courses that were unaffected by their hydroxyurea use. They continued taking the drug at full dose throughout treatment for those infections without complications. This suggests that while hydroxyurea reduces the raw number of immune cells, it doesn’t create the kind of deep immunosuppression seen with drugs designed specifically to shut down the immune system, like those used after organ transplants.
Why It Still Gets Treated Like an Immunosuppressant
Despite the reassuring infection data, hydroxyurea carries real immunosuppressive consequences in certain clinical situations. The CDC groups antimetabolites alongside other cancer drugs and states that patients receiving these medications should not receive live vaccines. Live vaccines contain weakened but active viruses or bacteria, and they rely on a functioning immune system to safely generate protection without causing disease. In someone whose bone marrow is suppressed, even a weakened pathogen could potentially cause harm. Inactivated vaccines remain safe to use.
There’s also the ongoing risk of the bone marrow being suppressed too aggressively. If white blood cell counts or platelet counts drop too low, patients become vulnerable to serious infections and bleeding. This is why regular blood monitoring is a non-negotiable part of hydroxyurea therapy. Guidelines recommend blood counts at least every two to three months once a patient is on a stable dose, and monthly during the initial period when the dose is being adjusted. Most treatment centers schedule a minimum of four monitoring appointments per year.
What Hydroxyurea Is Prescribed For
Hydroxyurea’s most common use today is for sickle cell disease, where it remains the most effective drug for reducing painful crises, acute chest syndrome, and severe anemia. It works in sickle cell patients through multiple pathways: boosting fetal hemoglobin (a form of hemoglobin that resists sickling), lowering inflammatory white blood cells, and reducing the stickiness of blood cells.
It’s also used for myeloproliferative disorders, conditions where the bone marrow overproduces certain blood cells. These include some forms of leukemia and polycythemia vera. In these cases, suppressing the overactive marrow is the entire goal. The drug has additionally been used in melanoma and ovarian cancer treatment, though newer therapies have largely replaced it in oncology.
Long-Term Safety Considerations
One concern that comes up with long-term use of any drug that affects DNA replication is whether it raises cancer risk. A large study of over 4,000 older patients with myeloproliferative disorders followed for a median of about three years found no significant difference in cancer incidence between hydroxyurea users and non-users. The rate of developing leukemia or a related blood cancer was nearly identical: 1.87% for hydroxyurea users versus 1.99% for non-users. The one area where data is less clear is non-melanoma skin cancers, which some smaller studies have linked to hydroxyurea use but which couldn’t be evaluated in the larger study due to reporting limitations.
The bottom line: hydroxyurea is not classified as an immunosuppressant, but it functionally suppresses part of the immune system by reducing white blood cell production. In practice, this means you’ll be treated as immunocompromised for purposes like vaccination decisions and infection monitoring, even though the drug doesn’t target the immune system the way dedicated immunosuppressants do. The degree of suppression is typically moderate and carefully controlled through regular blood work.